List view / Grid view
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Opaganib reduced blood clot length and weight in a pre-clinical model of Acute Respiratory Distress Syndrome (ARDS).
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Study shows that haematoxylin can selectively kill cancers with a mutated form of the calreticulin gene (CALR), common in a group of bone marrow cancers called myeloproliferative neoplasms (MPNs).
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
Mice treated with a small molecule inhibitor of cadherin 11 (CDH11) had reduced pancreatic cancer growth and increased survival time.
Investigators found that red propolis can kill schistosomes at all stages of development and therefore suggest it could be highly effective for treating schistosomiasis.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse…
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
